TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The FDA is requiring labeling for all GLP-1 receptor agonist medications to warn about a potential increased risk of nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause sudden, permanent vision loss. Its review found 15 probable cases across clinical trials and a higher incidence rate among GLP-1 users than in the comparison group, but the agency has not established that the medicines cause the condition.
The U.S. Food and Drug Administration is requiring warning-label updates for all GLP-1 receptor agonist medications to describe a potential risk of NAION, a rare eye condition that can cause sudden, permanent vision loss. The FDA said its review found a higher incidence rate among people taking GLP-1 medicines than among patients receiving placebo or other glucose-lowering drugs, but it has not established that the medicines cause the condition.
The condition, nonarteritic anterior ischemic optic neuropathy, or NAION, involves reduced blood flow to the optic nerve. The FDA says it can cause acute, painless, decreased vision in one eye, with vision loss that may be permanent. There is currently no treatment that reverses vision loss from NAION, according to the report.
The agency reviewed 126 clinical trials involving more than 134,200 patients and identified 15 probable NAION cases: 10 among patients taking a GLP-1 medicine and five among those receiving placebo. It identified no cases among patients taking glucose-lowering medicines that were not GLP-1 drugs. The FDA calculated an incidence rate of 6.4 cases per 100,000 person-years among GLP-1 patients, compared with 3.8 among patients receiving placebo or alternative glucose-lowering medicines.
The labeling requirement applies across the class, including products such as Ozempic, Wegovy, Mounjaro, Zepbound and Soliqua. The FDA said cases have been reported for all currently marketed GLP-1 receptor agonists. The report does not say that every product has the same level of risk, or that the review established a causal relationship.
What the Label Warning Means
The change puts a rare but potentially serious eye condition into the safety information patients and prescribers receive for GLP-1 medicines used for diabetes and, for some products, obesity. Because NAION can cause sudden vision loss and has no treatment to reverse that loss, the warning may be relevant when patients and clinicians discuss medication risks and new vision symptoms.
The findings are a safety signal, not proof that the drugs cause NAION. The rates reported by the FDA are expressed per 100,000 person-years, rather than as an individual’s personal probability of developing the condition. Patients should not stop or change a prescribed medication solely on the basis of the warning without discussing it with their health care professional. Sudden vision changes warrant prompt medical attention.
Products Worth Considering
Oura Ring 5 Smart Ring, Gold, Size 10
Blueair Blue Pure 511i Max Smart Air Purifier
Therabody Theragun Mini 3rd Generation Massage Gun, Black
As an affiliate, we earn on qualifying purchases.
How the FDA Reached Its Decision
The FDA began examining a possible link after a 2024 study published in JAMA Ophthalmology reported an increased risk of NAION among patients using GLP-1 medicines. The agency noted limitations in that study but said it considered further evaluation warranted. Its later review drew on 126 clinical trials, totaling more than 134,200 participants.
NAION is described as the most common cause of acute optic nerve injury among people over 50. The report gives an annual average of 2.3 to 10.2 cases per 100,000 people over 50. Diabetes, smoking, high blood pressure and high cholesterol are among its known risk factors. These background figures do not show that GLP-1 medicines caused any individual case.
“FDA concluded that there is a potential increased risk of rare NAION events in patients taking GLP-1 RAs.”
— The U.S. Food and Drug Administration
What the Evidence Does Not Establish
The FDA described a potential increased risk, but the information reported does not establish that GLP-1 medicines directly cause NAION. The review identified 15 probable cases across trials, a small number compared with the more than 134,200 participants, and the available summary does not provide product-by-product rates or a breakdown of patients’ individual risk factors.
Novo Nordisk said the data do not establish cause and effect. The Guardian reported that it had sought comment from Eli Lilly and Sanofi; the supplied report does not include responses from either company. It also does not specify when every affected product’s revised labeling will appear or what additional evidence may clarify the risk.
Label Updates and Safety Monitoring
Manufacturers covered by the FDA action are required to add NAION information to the Warnings and Precautions section of their product labeling. Patients can expect the risk to be described in updated medication information, although the report does not give a timetable for when each label will be revised.
The FDA and drugmakers are expected to continue monitoring safety information as more data become available. Patients taking these medicines should raise questions about the warning with their prescriber and seek prompt medical care for sudden vision changes. The evidence and any further regulatory action remain subject to ongoing review.
Key Questions
What is NAION?
NAION is a condition involving reduced blood flow to the optic nerve. The FDA says it can cause sudden, painless decreased vision in one eye, and the loss may be permanent.
Which medicines are covered by the FDA warning?
The labeling requirement covers all GLP-1 receptor agonist medicines, including products named in the report such as Ozempic, Wegovy, Mounjaro, Zepbound and Soliqua.
Did the FDA prove that GLP-1 medicines cause blindness?
No. The FDA identified a potential increased risk of rare NAION events, but the reported findings do not establish a cause-and-effect relationship. Novo Nordisk also said the data do not establish causation.
Should patients stop taking their medication?
The report does not advise patients to stop treatment. Anyone with questions about the warning should discuss them with their prescriber before changing a medication. Sudden vision changes should receive prompt medical attention.
Source: theguardian.com
